WIBG Inhibitors
Chemical inhibitors of WIBG can interfere with its function in various ways, leveraging the intricate pathways of cellular signaling and protein interactions. Staurosporine, by inhibiting protein kinase C (PKC), can alter the phosphorylation status and activity of proteins that associate with WIBG, thereby affecting WIBG's role in RNA processing. Similarly, H-89 targets protein kinase A (PKA), and its inhibitory action can lead to changes in the phosphorylation and function of WIBG-interacting proteins. The kinase inhibitor K252a also disrupts the activity of several protein kinases, which can modify the signaling pathways involving WIBG, impacting its function in mRNA binding and translation.
Furthermore, DRB targets RNA Polymerase II, which stalls mRNA synthesis and indirectly limits the substrate availability for WIBG, influencing its functional capacity in mRNA processing. The chemicals Wortmannin and LY294002, both PI3K inhibitors, can disrupt PI3K-dependent signaling, potentially altering the cellular environment and affecting processes that involve WIBG. Rapamycin, by inhibiting mTOR, can affect protein synthesis and consequently the translation of proteins that interact with WIBG. The selective CDK inhibitor Roscovitine can reduce WIBG's involvement in RNA splicing and export by altering the activity of CDK-related proteins. Moreover, inhibitors like SP600125, U0126, SB203580, and PD98059 target various kinases such as JNK, MEK1/2, p38 MAP Kinase, and MEK, respectively. These inhibitors can alter the phosphorylation states of proteins within signaling pathways that influence the stability, processing, and metabolism of mRNA, thereby functionally inhibiting WIBG's role in these critical cellular processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinase C (PKC), which is essential in multiple signaling pathways, including those regulating RNA processing factors like WIBG. Inhibition of PKC can lead to reduced phosphorylation and activity of proteins that interact with WIBG, thus functionally inhibiting WIBG. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
This chemical, known as DRB, inhibits RNA Polymerase II, which is crucial for the transcription of mRNA. Since WIBG is involved in mRNA binding and translation, inhibition of mRNA synthesis can indirectly inhibit the function of WIBG by limiting its substrate availability. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a potent inhibitor of protein kinase A (PKA). Given that PKA can phosphorylate substrates that may interact with WIBG, its inhibition can lead to a decrease in the functional activity of proteins that associate with WIBG, thereby inhibiting WIBG's role in mRNA processing. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it can indirectly inhibit WIBG by disrupting signaling pathways that control cell growth and protein synthesis, potentially altering the cellular environment in which WIBG functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the mTORC1 complex that regulates protein synthesis. WIBG function is connected to protein synthesis; thus, rapamycin may indirectly inhibit WIBG by reducing the translation of proteins that interact with WIBG. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Similar to Wortmannin, LY294002 is an inhibitor of PI3K. It can indirectly inhibit WIBG by disrupting PI3K-dependent signaling pathways, thereby influencing the processes that WIBG is involved in, such as mRNA splicing and translation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a selective inhibitor of cyclin-dependent kinases (CDKs). Since CDKs can phosphorylate proteins that associate with WIBG, their inhibition may lead to a reduction in WIBG-related processes like RNA splicing and export. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This chemical is an inhibitor of c-Jun N-terminal kinase (JNK). JNK pathway influences transcription factors and other proteins that may interact with WIBG, thus SP600125 can indirectly inhibit WIBG by affecting these interactions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibition of this pathway can alter the phosphorylation state of proteins that are potential interactors of WIBG, thus functionally inhibiting WIBG. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP Kinase inhibitor. Since p38 MAPK is involved in stress responses and mRNA decay, its inhibition can lead to a functional inhibition of WIBG by affecting the stability and processing of mRNA substrates that WIBG interacts with. | ||||||